News

PharmExec3d
FDA Updates Prescribing Information for Bristol Myers Squibb’s Camzyos to Reduce Echocardiography Monitoring Requirements
The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...
Zoloft vs. Lexapro: A comprehensive comparison of two leading SSRIs
SaveHealth assesses the relative benefits of Zoloft vs. Lexapro, comparing their usage, effectiveness, tolerability, ...
Medical Dialogues6d
USFDA updates Camzyos label to reduce echocardiography monitoring requirements, contraindications: Bristol Myers Squibb
Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.